IJOC  Vol.3 No.1 A , April 2013
Solid Phase Synthesis of 3,4,5-Trisubstituted-1,2,4-Triazoles Derivatives from the Resin-Bound Acylhydrazines
ABSTRACT

An extension of our methodology on solid-phase synthesis of 3,4,5-trisubstituted-1,2,4-triazoles under mild conditions has been developed. Firstly, the resin-bound acylhydrazine is reacted with orthoesters to provide resin-bound 1,3,4-oxadiazoles. Secondly, condensation of 1,3,4-oxadiazoles resin with the corresponding arylamines hydrochloride to form the the resin-bound triazoles. 3,4,5-Trisubstituted-1,2,4-triazoles derivatives were obtained from resin-bound acylhydrazines in several steps providing 78% - 87% overall yields and excellent purity. The advantages of this method include straightforward operation and high yield and purity of the products.


Cite this paper
R. Xie, X. Liu, C. Mai and Z. Liu, "Solid Phase Synthesis of 3,4,5-Trisubstituted-1,2,4-Triazoles Derivatives from the Resin-Bound Acylhydrazines," International Journal of Organic Chemistry, Vol. 3 No. 1, 2013, pp. 35-40. doi: 10.4236/ijoc.2013.31A004.
References
[1]   A. Curtis and N. Jennings, “1,2,4-Triazoles,” In: A. R. Katritzky, C. A. Ramsden, E. F. V. Scriven and R. J. K. Taylor, Eds., Comprehensive Heterocyclic Chemistry III, Vol. 5, Elsevier Ltd., New York, 2008, pp. 159-209.

[2]   K. D. Patel, B. D. Mistry and K. R. Desai, “Synthesis and Antimicrobial Activity of 1,2,4-Triazoles,” Journal of Indian Chemical Society, Vol. 79, No. 9, 2002, pp. 964-965.

[3]   K. Shalini, N. Kumar, S. Drabu and P. K. Sharma, “Advances in Synthetic Approach to and Antifungal Activity of Triazoles,” Beilstein Journal of Organic Chemistry, Vol. 7, 2011, pp. 668-677. doi:10.3762/bjoc.7.79

[4]   K. Colanceska-Ragenovic, V. Dimova, V. Kakurinov, D. G. Molnar and A. Buzarovska, “Synthesis, Antibacterial and Antifungal Activity of 4-Substituted-5-Aryl-1,2,4Triazoles,” Molecules, Vol. 6, No. 10, 2001, pp. 815-824. doi:10.3390/61000815

[5]   B. S. Holla, K. N. Poorjary, B. S. Rao and M. K. Shivananda, “New Bis-Aminomercaptotriazoles and BisTriazolothia-Diazoles as Possible Anticancer Agents,” European Journal of Medicinal Chemistry, Vol. 37, No. 6, 2002, pp. 511-517. doi:10.1016/S0223-5234(02)01358-2

[6]   G. Turan-Zitouni, Z. A. Kaplancikli, A. Özdemir, P. Chevallet, H. B. Kandilci and B. Gümüsel, “Studies on 1,2, 4-Triazole Derivatives as Potential Anti-Inflammatory Agents,” Archiv der Pharmazie, Vol. 340, No. 11, 2007, pp. 586-590. doi:10.1002/ardp.200700134

[7]   G. R. Jadhav, M. U. Shaikh, R. P. Kale, M. R. Shiradkar and C. H. Gill, “SAR Study of Clubbed [1,2,4]-Triazolyl with Fluorobenzimidazoles as Antimicrobial and Antituberculosis Agents,” European Journal of Medicinal Chemistry, Vol. 44, No. 7, 2009, pp. 2930-2935. doi:10.1016/j.ejmech.2008.12.001

[8]   S. Borg, G. Estenne-Bouhtou, K. Luthman, I. Csöregh, W. Hesselink and U. Hacksell, “Synthesis of 1,2,4-Oxadiazole-1,3,4-Oxadiazoleand 1,2,4-Triazole-Derived Dipeptidomimetics,” The Journal of Organic Chemistry Vol. 60, No. 10, 1995, pp. 3112-3120. doi:10.1021/ jo00115a029

[9]   C. Chen, R. Dagnino, C. Q. Huang, J. R. McCarthy and D. E. Grigoriadis, “1-Alkyl-3-Amino-5-Aryl-1H-[1,2,4]Triazoles: Novel Synthesis via Cyclization of N-Acyl-S-Methylisothioureas with Alkylhydrazines and Their Potent Corticotropin-Releasing Factor-1 (CRF1) Receptor Antagonist Activities,” Bioorganic & Medicinal Chemistry Letters, Vol. 11, No. 24, 2001, pp. 3165-3168. doi:10.1016/S0960-894X(01)00657-6

[10]   S. K. Thompson, A. M. Eppley, J. S. Frazee, M. G. Darcy, R. T. Lum, T. A Tomaszek, L. A. Ivanoff, J. F. Morris, E. J. Sternberg, D. M. Lambert, A. V. Fernandez, S. R. J. Petteway, T. D. Meek, B. W. Metcalf and J. G. Gleason, “Synthesis and Antiviral Activity of a Novel Class of HIV-1 Protease Inhibitors Containing a Heterocyclic P1’P2’ Amide Bond Isostere,” Bioorganic & Medicinal Chemistry Letters, Vol. 4, No. 20, 1994, pp. 2441-2446. doi:10.1016/S0960-894X(01)80406-6

[11]   F. Kevin, “Triazole Derivatives and Their Preparation and Method for Treating Non-Hodgkin’s Lymphoma,” US Patent No. 2006-808341, 2007.

[12]   M. H. Klingele and S. Brooker, “The Coordination Chemistry of 4-Substituted 3,5-Di(2-Pyridyl)-4H-1,2,4-Triazoles and Related Ligands,” Coordination Chemistry Reviews, Vol. 241, No. 1-2, 2003, pp. 119-132. doi:10.1016/S0010-8545(03)00049-3

[13]   G. Aromí, L. A. Barrios, O. Roubeau and P. Gamez, “Triazoles and Tetrazoles: Prime Ligands to Generate Remarkable Coordination Materials,” Coordination Chemistry Reviews, Vol. 255, No. 5-6, 2011, pp. 485-546. doi:10.1016/j.ccr.2010.10.038

[14]   X. W. Chen, C. Y. Liu, T. H. Jen, S. A. Chen and S. Holdcroft, “Synthesis and Characterization of a Fullerene Bearing a Triazole Group,” Chemistry of Materials, Vol. 19, No. 20, 2007, pp. 5194-5199. doi:10.1021/cm071686y

[15]   Z. Y. Zhou, X. W. Chen and S. Holdcroft, “Stabilizing Bicontinuous Nanophase Segregation in πCP-C60 DonorAcceptor Blends,” Journal of the American Chemical Society, Vol. 130, No. 35, 2008, pp. 11711-11718. doi:10.1021/ja802021z

[16]   P. L. Wu, X. J. Feng, H. L. Tam and K. W. Cheah, “Efficient Three-Photon Excited Deep Blue Photoluminescence and Lasing of Diphenylamino and 1,2,4-Triazole Endcapped Oligofluorenes,” Journal of the American Chemical Society, Vol. 131, No. 3, 2009, pp. 886-887. doi:10.1021/ja806703v

[17]   S. J. Haycock-Lewandowski, N. J. Mawby, A. Wilder and J. Ahman, “Development of a Bulk Enabling Route to Maraviroc (UK-427,857), a CCR-5 Receptor Antagonist,” Organic Process Research & Development, Vol. 12, No. 6, 2008, pp. 1094-1103. doi:10.1021/op8000614

[18]   S. Fustero, J. Gonzalez and C. Del Pozo, “1,4-Benzodiazepine N-Nitrosoamidines: Useful Intermediates in the Synthesis of Tricyclic Benzodiazepines,” Molecules, Vol. 11, No. 8, 2006, pp. 583-588. doi:10.3390/11080583

[19]   K. B. Hansen, J. Balsells, S. Dreher, Y. Hsiao, M. Kubryk, M. Palucki, N. Rivera, D. Steinhuebel, J. D. Armstrong III, D. Askin and E. J. Grabowski, “First Generation Process for the Preparation of the DPP-IV Inhibitor Sitagliptin,” Organic Process Research & Development, Vol. 9, No. 5, 2005, pp. 634-639. doi:10.1021/op0500786

[20]   A. Moulin, M. Bibian, A. L. Blayo, S. E. Habnouni, J. Martinez and J. A. Fehrentz, “Synthesis of 3,4,5-Trisubstituted-1,2,4-Triazoles,” Chemical Reviews, Vol. 110, No. 4, 2010, pp. 1809-1827. doi:10.1021/cr900107r

[21]   N. I. Korotkikh, A. V. Kiselev, A. V. Knishevitsky, G. F. Raenko, T. M. Pekhtereva and O. P. Shvaika, “Recyclization of 1, 3, 4-Oxadiazoles and Bis-1,3,4-Oxadiazoles into 1,2,4-Triazole Derivatives. Synthesis of 5-Unsubstituted 1,2,4-Triazoles,” Chemistry of Heterocyclic Compounds, Vol. 41, No. 7, 2005, pp. 866-871. doi:10.1007/s10593-005-0240-2

[22]   N. A. Meanwell, J. L. Romine, M. J. Rosenfeld, S. W. Martin, A. K. Trehan, J. J. K. Wright, M. F. Malley, J. Z. Gougoutas, C. L. Brassard, J. O. Buchanan, M. E. Federic, J. S. Fleming, M. Gamberdella, K. S. Hartl, G. B. Zavoico and S. M. Seiler, “Nonprostanoid Prostacyclin Mimetics 5. Structure-Activity-Relationships Associated with [3-[4(4,5-Diphenyl-2-Oxazolyl)-5-Oxazolyl] Phenoxy] Acetic Acid,” Journal of Medicinal Chemistry, Vol. 36, No. 24, 1993, pp. 3884-3903. doi:10.1021/jm00076a018

[23]   M. J. Stocks, D. R. Cheshire and R. Reynolds, “Efficient and Regiospecific One-Pot Synthesis of Substituted 1,2, 4-Triazoles,” Organic Letters, Vol. 6, No. 17, 2004, pp. 2969-2971. doi:10.1021/ol048863a

[24]   J. Lindström and M. H. Johansson, “Synthesis of 3-Aryl5-Methyl 4-Substituted [1,2,4] Triazoles,” Synthetic Communications, Vol. 36, No. 15, 2006, pp. 2217-2229. doi:10.1080/00397910600638994

[25]   A. J. Duplantier, E. L. Bachert, J. B. Cheng, V. L. Cohan, T. H. Jenkinson, K. G. Kraus, M. W. McKechney, J. D. Pillar and J. W. Watson, “SAR of a Series of 5,6-Dihydro-(9H)-Pyrazolo [3,4-c]-1,2,4-Triazolo[4,3-Alpha]Pyridines as Potent Inhibitors of Human Eosinophil Phosphodiesterase,” Journal of Medicinal Chemistry, Vol. 50, No. 2, 2007, pp. 344-349. doi:10.1021/jm060904g

[26]   B. Modzelewska-Banachiewicz, J. Banachiewicz, A. Chodkowska, E. Jagiello-Wojtowicz and L. Mazur, “Synthesis and Biological Activity of New Derivatives of 3-(3,4-Diaryl-1,2,4-Triazole-5-yl)Propenoic Acid,” European Journal of Medicinal Chemistry, Vol. 39, No. 10, 2004, pp. 873-877. doi:10.1016/j.ejmech.2004.07.002

[27]   B. Modzelewska-Banachiewicz, M. Ucherek, M. Zimecki, J. Kutkowska, T. Kaminska, B. Morak-Mlodawska, R. Paprocka, M. Szulc, G. Lewandowski, J. Marciniak and T. Bobkiewicz-Kozlowska, “Reactions of N3-Substituted Amidrazones with Cis-1,2-Cyclohexane Dicarboxylic Anhydride and Biological Activitiesof the Products,” Archiv der Pharmazie, Vol. 345, No. 6, 2012, pp. 486-494. doi:10.1002/ardp.201100333

[28]   S. Olson, S. D. Aster, K. Brown, L. Carbin, D. W. Graham, A. Hermanowski-Vosatka, C. B. LeGrand, S. S. Mundt, M. A. Robbins, J. M. Schaeffer, L. H. Slossberg, M. J. Szymonifka, R. Thieringer, S. D. Wright and J. M. Balkovec, “Adamantyl Triazoles as Selective Inhibitors of 11 Beta-Hydroxysteroid Dehydrogenase Type 1,” Bioorganic & Medicinal Chemistry Letters, Vol. 15, No. 19, 2005, pp. 4359-4362. doi:10.1016/j.bmcl.2005.06.040

[29]   M. A. García, S. Martín-Santamaría, M. Cacho, F. M. Llave, M. Julian, A. Martínez, B. Pascual-Teresa and A. Ramos, “Synthesis, Biological Evaluation, and ThreeDimensional Quantitative Structure-Activity Relationship Study of Small-Molecule Positive Modulators of Adrenomedullin,” Journal of Medicinal Chemistry, Vol. 48, No. 12, 2005, pp. 4068-4075. doi:10.1021/jm050021+

[30]   M. Saitoh, J. Kunitomo, E. Kimura, H. Iwashita, Y. Uno, T. Onishi, N. Uchiyama, T. Kawamoto, T. Tanaka, C. D. Mol, D. R. Dougan, G. P. Textor, G. P. Snell, M. Takizawa, F. Itoh and M. Kori, “2-{3-[4-(Alkylsulfinyl)Phenyl]1-Benzofuran-5-yl}-5-Methyl-1,3,4-Oxadiazole Derivatives as Novel Inhibitors of Glycogen Synthase Kinase-3 Beta with Good Brain Permeability,” Journal of Medicinal Chemistry, Vol. 52, No. 20, 2009, pp. 6270-6286. doi:10.1021/jm900647e

[31]   A. Brown, D. Ellis, D. Pearce, M. Ralph and N. Sciammetta, “Aryloxypyrazines as Highly Selective Antagonists of Oxytocin,” Bioorganic & Medicinal Chemistry Letters, Vol. 19, No. 10, 2009, pp. 2634-2636. doi:10.1016/j.bmcl.2009.03.160

[32]   T. Sugane, T. Tobe, W. Hamaguchi, I. Shimada, K. Maeno, J. Miyata, T. Suzuki, T. Kimizuka, A. Kohara, T. Morita, H. Doihara, K. Saita, M. Aota, M. Furutani, Y. Shimada, N. Hamada, S. Sakamoto and S. Tsukamoto, “Synthesis and Biological Evaluation of 3-Biphenyl-4-yl4-Phenyl-4H-1,2,4-Triazoles as Novel Glycine Transporter 1 Inhibitors,” Journal of Medicinal Chemistry, Vol. 54, No. 1, 2011, pp. 387-391. doi:10.1021/jm101031u

[33]   P. H. J. Carlsen and K. B. JØrgensen, “Synthesis of Unsymmetrically Substituted 4H-1,2,4-Triazoles,” Journal of Heterocyclic Chemistry, Vol. 31, 1994, pp. 805-807.

[34]   X. F. Chen, R. Liu, Y. Xu and G. Zou, “Tunable Protic Ionic Liquids as Solvent-Catalysts for Improved Synthesis of Multiply Substituted 1,2,4-Triazoles from Oxadiazoles and Organoamines,” Tetrahedron, Vol. 68, 2012, pp. 4813-4819. doi:10.1016/j.tet.2012.03.114

[35]   P. Seneci, “Solid Phase Synthesis and Combinatorial chemistry,” Wiley InterscienceJohn, Wiley & Sons, New York, 2000.

[36]   R. E. Dolle, “Comprehensive Survey of Combinatorial Library Synthesis,” Journal Combintorial Chemistry, Vol. 6, No. 5, 2004, pp. 623-679. doi:10.1021/cc0499082

[37]   P. H. Toy and Y. Lam, “Solid-Phase Organic Synthesis Concepts, Strategies, and Ap-plications,” John Wiley & Sons, Inc., Hoboken, 2012.

[38]   A. R. Katritzky, M. Qi, D. Feng, G. Zhang, M. C. Griffith and K. Watson, “Synthesis of 1,2,4-Triazole-Functionalized Solid Support and Its Use in the Solid-Phase Synthesis of Trisubstituted 1,2,4-1,2,4-Triazoles,” Organic Letters, Vol. 1, No. 8, 1999, pp. 1189-1191. doi:10.1021/ol990186a

[39]   S. D. Larsen and B. A. DiPaolo, “Traceless Solid-Phase Synthesis of 1,2,4-Triazoles Using a Novel Amine Resin,” Organic Letters, Vol. 3, No. 21, 2001, pp. 3341-3344. doi:10.1021/ol016578a

[40]   Y. G. Wang, W. M. Xu and X. Huang, “Selenium-Based SafetyCatch Linker: Solid-Phase Synthesis of Vinyl-Substituted Oxadiazoles and Triazoles,” Journal of Combinatorial Chemistry, Vol. 9, No. 3, 2007, pp. 513-519. doi:10.1021/cc0700187

[41]   Z. X. Liu, J. L. Zhao and X. Huang, “Solid-Phase Synthesis of 1,3,4-Oxadiazoline-5-Thione Derivatives from Resin Bound Acylhydrazines,” Bioorganic & Medicinal Chemistry Letters, Vol. 16, No. 7, 2006, pp. 1828-1830. doi:10.1016/j.bmcl.2006.01.002

[42]   Z. X. Liu, Y. Y. Mu, J. Lin and Y. Y. Chen, “Traceless Solid-Phase Synthesis of 1, 2, 3-Thiadiazole Derivatives from Resin-Bound Acylhydrazine,” Synthetic Communications, Vol. 38, No. 24, 2008, pp. 4407-4414. doi:10.1080/00397910802369521

[43]   Z. X. Liu, Y. Y. Mu and Z. S. Song, “Solid Phase Synthesis of 4,5-Disubstituted 1, 2, 4-Triazol-3-One Derivatives from Resin-Bound Acylhydrazines,” Journal of Chemical Research, No. 4, 2008, pp. 216-217.

[44]   Z. X. Liu, Z. S. Song, J. L. Zhao and J. Y. Zheng, “SolidPhase Synthesis of 2-Arylamino-5-(4-Hydroxyphenyl)-1, 3,4-Thiadiazole Derivatives Based on Resin-Bound Acylhydrazines,” Phosphorus, Sulfur and Silicon and the Related Elements, Vol. 185, No. 11, 2010, pp. 2375-2381. doi:10.1080/10426501003664176

[45]   Z. X. Liu, Y. R. Yi, J. L. Zhao and M. X. Tang, “SolidPhase Synthesis of 4,5-Disubstituted-1,2,4-Triazole-3-Thione Derivatives Based on the Resin-Bound Acylhydrazines,” Synthetic Communications, Vol. 42, No. 1, 2012, pp. 5561. doi:10.1080/00397911.2010.521609

[46]   M. Dabiri, P. Salehi, M. Baghbanzadeh and M. Bahramnejad, “Alum (KAl(SO4)2.12H2O): An Efficient and Inexpensive Catalyst for the One-Pot Synthesis of 1,3,4Oxadiazoles under Solvent-Free Conditions,” Monatshefte für Chemie-Chemical Monthly, Vol. 138, No. 12, 2007, pp. 1253-1255. doi:10.1007/s00706-007-0724-0

 
 
Top